BONST
TEVA icon

Bank of Nova Scotia Trust’s Teva Pharmaceuticals TEVA Stock Holding History

Bank of Nova Scotia Trust’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-241
Closed -$4K – 359
2017
Q3 		$4K Buy
+241
New +$5.42K ﹤0.01% 399

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Bank of Nova Scotia Trust's TEVA Position: Q4 2017 in Review

Bank of Nova Scotia Trust sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 241 shares — an estimated $4K sold.

Bank of Nova Scotia Trust first reported a position in TEVA in Q3 2017 and held it in 1 quarter. The position peaked at $4K in Q3 2017. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Bank of Nova Scotia Trust reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Bank of Nova Scotia Trust sold 241 Teva Pharmaceuticals shares in Q4 2017, an estimated $4K.
  • Bank of Nova Scotia Trust first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Bank of Nova Scotia Trust's Teva Pharmaceuticals position peaked at $4K in Q3 2017.
  • 508 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Bank of Nova Scotia Trust's 13F filing for Q4 2017, filed 13 Feb 2018.